EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access · CC BY 4.0

Empagliflozin Use Is Associated With Lower Risk of All‐Cause Mortality, Hospitalization for Heart Failure, and End‐Stage Renal Disease Compared to DPP‐4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study

Gisle Langslet, Thomas Nyström, Dorte Vistisen, Bendix Carstensen, Emilie Toresson Grip, Paula Casajust iD, Giorgi Tskhvarashvili, Fabian Hoti, Riho Klement, Kristina Karlsdotter, Mikko Tuovinen, Anne Pernille Ofstad und 6 weitere

Journal of Diabetes Research · 2024

DOI: 10.1155/2024/6142211 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Diabetes Research, 2024. Verfasst von Gisle Langslet und 17 weiteren Autor:innen. Beteiligte Einrichtung: Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital 0424, Oslo, Norway. Hauptthemen laut MEDLINE: Glucosides, Diabetes Mellitus, Type 2, Benzhydryl Compounds, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the effectiveness of empagliflozin in reducing all‐cause mortality (ACM), hospitalization for heart failure (HHF), myocardial infarction (MI), stroke, cardiovascular mortality (CVM), and end‐stage renal disease (ESRD) in routine clinical practice in the Nordic countries of the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) study.

Methods

This noninterventional, multicountry cohort study used secondary data from four Nordic countries (Denmark, Sweden, Finland, and Norway). Propensity score (PS) matched (1:1) adults with type 2 diabetes (T2D) initiating empagliflozin (a sodium‐glucose cotransporter‐2 inhibitor) during 2014–2018 who were compared to those initiating a dipeptidyl peptidase‐4 inhibitor (DPP‐4i). Cox proportional hazards regression modelling was used to assess the risk for ACM, HHF, MI, stroke, CVM, and ESRD. Meta‐analyses were conducted and hazard ratios (HRs) with 95% confidence intervals (CIs) from random‐effects models were calculated.

Results

A total of 43,695 pairs of PS‐matched patients were identified. Patients initiating empagliflozin exhibited a 49% significantly lower risk of ACM (HR: 0.51, 95% CI 0.40–0.64) compared to DPP‐4i. Additionally, empagliflozin was associated with a 36% significantly lower risk of HHF (HR: 0.64, 95% CI 0.46–0.89), a 52% significantly lower risk of CVM (HR: 0.48, 95% CI 0.37–0.63), and a 66% significantly lower risk of ESRD (HR: 0.34, 95% CI 0.15–0.77) compared to DPP‐4i. No significant differences were observed in the risk of stroke and MI between patients initiating empagliflozin compared with those initiating a DPP‐4i. Results were generally consistent for subgroups (with/without pre‐existing CV disease or congestive heart failure) and in sensitivity analyses.

Conclusion

Empagliflozin initiation was associated with a significantly reduced risk of ACM, HHF, CVM, and ESRD compared with initiation of DPP‐4i in patients with T2D when examining routine clinical practice data from Nordic countries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesDiabetes Mellitus, Type 2Benzhydryl CompoundsDipeptidyl-Peptidase IV InhibitorsHeart FailureHospitalizationSodium-Glucose Transporter 2 InhibitorsKidney Failure, ChronicHumansMaleFemaleMiddle AgedAgedScandinavian and Nordic CountriesCohort StudiesTreatment Outcome

Stichwörter der Autor:innen

cardiovascular diseasescomparative effectivenessdipeptidyl peptidase-4 inhibitorsempagliflozinend-stage renal diseaseheart failuresodium-glucose cotransporter-2 inhibitorstype 2 diabetes mellitus

Substanzen

GlucosidesBenzhydryl CompoundsempagliflozinDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital 0424, Oslo, Norway.
  • Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet 118 83, Stockholm, Sweden.
  • Clinical Epidemiology, Steno Diabetes Center Copenhagen 2730, Herlev, Denmark.
  • A/I and Analytics, Novo Nordisk A/S, AI and Analytics, Søborg, Denmark.
  • Real World Data and Data Analytics, Quantify Research 11221, Stockholm, Sweden.
  • Department of Medicine, Karolinska Institutet 141 57, Huddinge, Sweden.

ORCID-Profile: Paula Casajust, Christina Shay, Sigrun Halvorsen

Zitieren

APA

Langslet, G., Nyström, T., Vistisen, D., Carstensen, B., Grip, E. T., Casajust, P., Tskhvarashvili, G., Hoti, F., Klement, R., Karlsdotter, K., Tuovinen, M., Ofstad, A. P., Lajer, M., Shay, C., Koeneman, L., Farsani, S. F., Niskanen, L., & Halvorsen, S. (2024). Empagliflozin Use Is Associated With Lower Risk of All‐Cause Mortality, Hospitalization for Heart Failure, and End‐Stage Renal Disease Compared to DPP‐4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study. Journal of Diabetes Research. https://doi.org/10.1155/2024/6142211

Vancouver

Langslet G, Nyström T, Vistisen D, Carstensen B, Grip ET, Casajust P, et al. Empagliflozin Use Is Associated With Lower Risk of All‐Cause Mortality, Hospitalization for Heart Failure, and End‐Stage Renal Disease Compared to DPP‐4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study. Journal of Diabetes Research. 2024. doi:10.1155/2024/6142211

BibTeX
@article{Langslet2024,
  author = {Langslet, Gisle and Nyström, Thomas and Vistisen, Dorte and Carstensen, Bendix and Grip, Emilie Toresson and Casajust, Paula and Tskhvarashvili, Giorgi and Hoti, Fabian and Klement, Riho and Karlsdotter, Kristina and Tuovinen, Mikko and Ofstad, Anne Pernille and Lajer, Maria and Shay, Christina and Koeneman, Lisette and Farsani, Soulmaz Fazeli and Niskanen, Leo and Halvorsen, Sigrun},
  title = {Empagliflozin Use Is Associated With Lower Risk of All‐Cause Mortality, Hospitalization for Heart Failure, and End‐Stage Renal Disease Compared to DPP‐4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study},
  journal = {Journal of Diabetes Research},
  year = {2024},
  doi = {10.1155/2024/6142211}
}
Kostenlos starten →